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Synthesis of new N-[3-(thieno[3,2-b]pyridine-7-ylthio)phenyl]benzamides as 
potential inhibitors the tyrosine kinase domain of VEGFR2 
Joana F. Campos8 , Agathe Begouin8 , Daniela Peixoto8 ,Hugo J. C. Froufeb, Rui M. V. Abreub, 
lsabel C.F.R. Ferreirab, Maria-Joao R.P. Queiroz8 
8 Centro de Qufmica , Esc o/a de Ciencias Uni versidade do Minho Campus de Gualta r 
4710-057 Braga 
bCentro de lnvestigar.;ao de Montanha (CIMO), ESA, lnst i tuto Politecnico de Braganr;a 
Campus de Santa Apol6nia, apart ado 1172, 5301 -855 Braganr.;a , 
Portugal;mjrpq@quimica. uminho. p t 
Angiogenesis, the growth of new vessels from preexisting vasculature, is a critical step in tumor 
progression [1]. The tyrosine kinase Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is 
a crucial mediator in angiogenesis since the VEGF, excreted by the tumor cells, binds to it 
activating several signaling pathways involved in cell survival and proliferation [2]. Recently 
thienopyridine derivatives showed to be promising inhibitors of the tyrosine kinase domain of 
VEGFR2 [3,4]. In this work new N-[3-(thieno[3,2-b]pyridine-7-ylthio)phenyl]benzamides were 
prepared as potential VEGFR2 inhibitors suggested by rational design, as presented below. 
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The inhibition of the tyrosine kinase domain of the VEGFR2 will be evaluated either by enzymatic 
or cellular and biomolecular assays using VEGF-stimulated Human Umbilical Vein Endothelial 
Cells (HUVECs) . 
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